• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
CCAIM

CCAIM

Novel AI to transform healthcare

  • Home
  • About
    • Our Aims
    • ISAB Report
  • People
    • Leadership
    • Faculty
    • Associate Faculty
    • Joint Steering Committee
    • Independent Scientific Advisory Board
    • Staff
    • Our students
    • Affiliated clinical PhD Students
    • Visitors
  • Research
    • Papers
    • Breakthroughs
    • Software
      • AutoPrognosis
      • HyperImpute
      • Interpretability Suite
      • Synthcity
      • TemporAI
    • Demonstrators
    • Research Update: COVID-19
    • Blog
  • News
    • Latest News
    • COVID-19 News
  • Events
    • Seminar Series
    • WeCREATE
    • Inaugural Event
    • AI Clinic 2023
    • AI Clinic 2022
  • Summer School
    • Summer School 2023
      • Participate
      • Program
      • Topics
      • Industry
      • FAQ
    • Summer School 2022
  • Get involved
    • PhD Programmes
    • Clinical PhD Position
    • Partners
    • Connect

Revolutionising Pharmacological Predictions: How Synthetic Model Combination (SMC) Could Change the Game for Drug Development

24 May 2023 by Andreas Bedorf

SMC builds a new ensemble weighting existing models according to their likelihood to accurately represent a novel case. Based on our results, SMC is more robust and gives more accurate predictions than existing models.

This work has been realised in a close collaboration of van der Schaar lab, CCAIM and AstraZeneca.

Clinical pharmacologists understand that patients are unique. Every patient has a biological system that responds differently to drugs and adjusting dosing to specific circumstances is often necessary. In clinical trials, trial and error can be time-consuming, and waiting weeks to learn how a patient responds to an investigational medicine is not always feasible. Mathematical models may be able to help make predictions about patient outcomes. However, what model should be used for the situation at hand?

Synthetic Model Combination (SMC), a machine learning method for constructing new model ensembles, is our newest answer to that question. SMC builds a new ensemble weighting existing models according to their likelihood to accurately represent a novel case. Based on our results, SMC is more robust and gives more accurate predictions than existing models, especially when there is no new data to judge which existing model is best. SMC can be reverse engineered to the needs of the situation and find applicable data for individuals who do not fit any of the existing models. This has the potential to really benefit – under-represented groups and special cases such as rare diseases and unique biological responses.

Pulling from a wide array of available models, when compared to trial-and-error and other methods: “SMC simply gives the best chance to get it right the first time”, Prof Richard Peck (CCAIM/University of Liverpool) says.

For drug developers, this is an exciting application as SMC provides a potential method to maximise the value of existing and new models to make more accurate predictions for new populations and new patients, ultimately improving the understanding of drug effects and how patients should be treated efficiently.

Prof Mihaela van der Schaar (CCAIM/University of Cambridge) has the following to say about the potential impact of SMC:

“I am tremendously excited about the possibilities that arise when machine learners and pharmacologists work together. By combining the power of cutting-edge technology with deep insights into the workings of the human body, we can unlock a new era of precision medicine. With more accurate predictions, clinicians will be able to develop new drugs more efficiently, and provide more effective personalised treatments, ultimately improving outcomes for patients around the world.“

SMC is flexible and can be used to understand and address a wide range of biological systems, pharmacological questions, and prediction-based approaches. As with all ensembling methods, SMC is only as good as the models fed into it but for now, SMC outperforms other ensembling methods. A big leap forward for drug developers and patients alike.

Comment from Megan Gibbs, (Vice President and Global Head, Clinical Pharmacology & Quantitative Pharmacology, AstraZeneca) :

“This publication is just one example of the potential for integrating AI into clinical pharmacology. Through closer collaboration between data scientists and clinical pharmacologists, we are able to improve our understanding of disease and its direct impact on patients’ lives.”

For a deeper understanding of how SMC works and how it can impact pharmacology, watch this short conversation between Prof Richard Peck and Alex Chan, leading contributors to the article:

You can find the full paper here.

Category: Impact, News, Research, Research NewsTag: Cambridge Centre for AI in Medicine, machine learning
Previous Post: « CCAIM at ICML 2023: 12 papers from our faculty
Next Post: Learning Representations without Compositional Assumptions »

Navigation

Home

News

About

University of Cambridge

  • University A-Z
  • Contact the University
  • Accessibility
  • Data Protection
  • Terms and conditions

Newsletter

Sign-up for updates on our research.

Follow us

  • Twitter
  • LinkedIn
  • YouTube

Copyright © 2023 CCAIM

Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

CCAIM
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!